Health Economics has been placed firmly at the center of policymakers' attention as an aging population faces ever increasing healthcare spending in the midst of a debt crisis. What role will cost effectiveness analyses play? See more here. (Source: EurActiv, 9/9/15) […]
Public Comment Sought on Cost Effectiveness in Health and Medicine
The Second Panel on Cost-Effectiveness in Health and Medicine is inviting public comment on selected draft chapters for its updated book, Cost-Effectiveness in Health and Medicine. See here for more information on the project and instructions about reading draft chapters and posting comments. […]
Researchers Propose Value Based for New Lung Cancer Drug
Researchers from Emory University and Georgia Institute of Technology recently developed an economic model to access the value-based cost of the lung cancer drug Necitumumab, despite the drug not yet receiving FDA approval. Find out more here. (Source: Journal of Clinical Pathways, 9/15/15) […]
Boston Watchdog Wants to End “What the Market will Bear” Pricing
Dr. Steven Pearson, president of the Institute for Clinical and Economic Review (ICER), is taking aim at rising pharmaceutical prices and could become a serious threat to the drug industry. See what the drug makers are so upset about here. (Source: Robert Weisman, Globe, 9/13/15) […]
Will Anthem’s New Pathway Program for Oncologist Succeed in Lowering Costs?
Anthem recently unveiled a new framework for treatment through its Cancer Care Quality Program in an effort to combat high pharmaceutical prices and ease the tense relationship between oncologist and insurers. Learn more here. (Source: Journal of Clinical Pathways, 9/8/15) […]
Another Failed Product – What Will GSK Do Now?
With GlaxoSmithKline's megablockbuster Advair soon to be experiencing fierce generic competition, investors were assured that the pharma giant had another remedy in hand. Excitement built around Breo Ellipta, a drug developed to improve the mortality rate of high-risk patients with COPD, but the […]
Should the US Look to Other Nations for Drug Cost Solutions?
Oncologists, Dr. Ezekiel Emanuel recently suggested a solution to the problem of high drug costs in the United States may be to look to other nations! What are other nations doing? Learn more here. (Source: Ezekiel Emanuel, The New York Times, 9/9/15) […]
What Should Pharmaceutical Drugs Really Cost?
The Drug Abacus is a new online tool developed by Dr. Bach and his colleagues at Memorial Sloan Kettering Cancer Center, which was developed to determine what a drug's "true" price should be. How does it work? Learn more here. (Source: Whitney McKnight, PM360, 9/10/15) […]
ICER Draft Report for PCSK9 Inhibitors Posted for Public Comment
The Institute for Clinical and Economic Review (ICER) recently released a new draft report, PCSK9 Inhibitor Therapies for High Cholesterol: Effectiveness, Value, and Value-Based Price Benchmarks. The report includes a comprehensive review of currently available evidence on newly approved PCSK9 […]
Complete Course Textbook on Cost Effectiveness Modeling in HTA
This book provides an introduction to decision analytic cost-effectiveness modelling, giving the theoretical and practical knowledge required to design and implement analyses that meet the methodological standards of health technology assessment organizations. The book is available for purchase as […]
3 Steps to Bring Pharmaceutical Pricing Within Reach
What 3 steps can we take to avoid controversies, administrative burden and ethical dilemmas produced by radical reactions to exorbitant pharmaceutical pricing? This post offers some information about drug pricing, explores the notion of market intervention, and proposes a series of responses to high […]
Guidelines Call for More Transparency on Hepatitis C Drug Costs
Updated guidelines from the American Association for the Study of Liver Diseases, the Infectious Diseases Society of America and the International Antiviral Society -USA attempt to provide an overview of hepatitis C virus treatments, including cost comparisons. Learn more here, login required. […]
Is a Drug’s Launch Price a Good Indicator of Future Expenditure?
How important is it to incorporate life-cycle price modeling when conducting cost-effectiveness analyses? A newly published OHE Research Paper shows how the traditional approach to calculating ICERs could lead to the wrong decision. Read more here. (Source: OHE, 8/25/15) […]
The Most Important Ingredients in any Analysis
The blog discusses the most important ingredient in a successful predictive value analysis model - the choice of the comparator. Read more here. (Source: Decision Driver Analytics, 7/23/15) […]
Gilead Pills Found Cost Effective at $1000/Day
A new report by an influential panel of 32 doctors and medical experts has found new Hepatits C drugs to be cost-effective given their benefits. What exactly does "cost-effective" mean and what impact will this have with health insurers? See more here. (Source: Doni Bloomfield, BloombergBusiness, […]
Nearly a Decade After Establishment of the Learning Health Care System – Has it Been Worth it?
During the recent ISPOR International Meeting, speakers discussed the Learning Health Care System and examined implications for researchers, payers, and patients. Has the investment in using Electronic data to track patients across health care providers and time paid off? See more here. (Source: […]
Call for Papers: Methods for Extrapolating Survival in Cost-Effectiveness Analyses
The goal of this special MDM themed issue is to bring wider attention to methodological advances in the area of extrapolation survival in cost-effectiveness analyses (CEA), and to provide a resource for future research and policy making. DEADLINE for manuscript submissions is June 30, 2015 with an […]
PPD and HealthCore Collaborate to Enhance Research Services
Pharmaceutical Product Development LLC (PPD) and HealthCore Inc recently announced a collaboration, enabling both companies to further expand their services in the pre- and post-approval research market with the aim of helping biopharmaceutical clients demonstrate more quickly and cost effectively […]
Check Out the Summer Issue of the University of Sheffield’s Health Economics Newsletter
The University of Sheffield's summer news letter is packed full of outcomes measurement, screening program me evaluations and online resources. Health Economics and Decision Science (HEDS) Newsletter, Summer 2015 is now available online. (Source: The University of Sheffield, Summer 2015) […]
Quick Recap of the American Diabetes Association’s 75th Scientific Sessions
The Academy of Managed Care Pharmacy (AMCP) offers a recap from the American Diabetes Association's 75th Scientific Sessions, looking at how expense impacts medication adherence. See more here. (Source: AMCP) […]
How Does the 21st Century Cures and Off-Label Promotion Benefit HEOR and Drug Safety?
Jim Davis, Executive Vice President of Adverse Events recently wrote a blog for tHEORetically Speaking on the benefits of the 21st Century Cures and Off-Label Promotion to HEOR and Drug Safety. Read more here. (Source: Jim Davis, tHEORetically Speaking, 6/4/15) […]
What is the Future of Health Economics Assessment of Drugs in France?
This article provides an in-depth description of the France's CEESP structure and working methods, and analyses the impact of health economic assessment on market access of drugs in France, as well as pointing out the areas of uncertainty and the conflicting rules following the introduction of the […]
Will Oncologists’ Push for Cost-Effectiveness Help Lower Pricing?
The American Society of Clinical Oncology recently held its annual conference in Chicago where pharmaceutical companies touted new cancer therapies and potential breakthroughs, however many speakers were focused on the skyrocketing costs of cancer drugs, calling for the explicit consideration of […]
Meet inVentiv Health experts at DIA
We are a global provider of best-in-class clinical development and comprehensive commercialization services to the biopharmaceutical industry. Visit us at the event: booth #1517. […]
Are Hepatitis C Drug Prices Going Beyond Cost Effectiveness?
This editorial takes a look at pharmaceutical pricing and reimbursement in Europe with particular focus on new treatments for Hepatitis C. Read more here. (Source: Eur J Health Econ, 11/19/14) […]
WHO Criticizes Pharma’s High Costs and Lack of Transparency
A new report recently released by the World Health Organization (WHO), found that governments are finding it increasingly difficult to afford new treatments and calls for greater transparency from the pharma industry as well as cooperation to help reduce drug prices. Read more here. (Source: Ben […]
The State of Cost-Utility Analysis in Asia
A data analysis from the Tufts Medical Center Cost-Effectiveness Analysis Registry. Take a look at cost-utility analyses (CUAs) features such as country of study, disease area researched, study funder, and type of intervention. Read more here. (Source: Teja Thorat, Tufts Medical Center, 4/6/15) […]
How Well Is Pharma Adapting To The New Health Economy?
This new report from PwC's Health Research Institute (HRI), The FDA and industry: a recipe for collaborating in the New Health Economy, shows a strong focus by consumers and insurers on cost-effectiveness as well as medical benefit will increase pressures on the FDA to consider similar changes. See […]
Download Ebook: Key Considerations for Market Access
In an era of austerity and rising health care costs, payers are exerting greater influence over pharmaceutical markets and demanding insight into a drug's value and cost effectiveness. Learn about the key considerations for market access in this ebook, available for download here. (Source: […]
Can US Stakeholders Get On The Same Page For Value Assessment?
The United States, unlike many developed countries with a national health service, lacks a uniform system to assess the value of drugs by insurers and a framework for describing decisions to key stakeholders. These issues were discussed during a session at the recent AMCP meeting. Read more here. […]
